• Almirall SA, of Barcelona, Spain, said the European Respiratory Journal published full results of ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts), a six-month pivotal study comparing the efficacy and safety of twice-daily inhaled aclidinium (200 mcg and 400 mcg) against placebo in patients with moderate to severe chronic obstructive pulmonary disease.